Phase II trial of Liposomal Grb-2 (BP 100-1-01) combination salvage therapy in patients with acute myeloid leukaemia

Trial Profile

Phase II trial of Liposomal Grb-2 (BP 100-1-01) combination salvage therapy in patients with acute myeloid leukaemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2016

At a glance

  • Drugs Prexigebersen (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 May 2016 According to a Bio-Path Holdings media release, this trial is enrolling patients in the efficacy part of the trial.
    • 03 Mar 2016 According to a Bio-Path Holdings media release, the company is in the process of submitting the results from this trial to the US FDA and is planning to open the efficacy portion of the Phase II trial of BP1001 in the second quarter of 2016.
    • 03 Mar 2016 Results from the eighth and final cohort of the safety segment of this trial published in a Bio-Path Holdings media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top